Skip to Content
Merck
All Photos(3)

Documents

327R-1

Sigma-Aldrich

PSMA (EP192) Rabbit Monoclonal Primary Antibody

Synonym(s):

Prostate-specific membrane antigen

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

UNSPSC Code:
12352203

biological source

rabbit

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP192, monoclonal

description

For In Vitro Diagnostic Use in Select Regions

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (327R-14)
vial of 0.1 mL concentrate Research Use Only (327R-14-RUO)
vial of 0.5 mL concentrate (327R-15)
vial of 1.0 mL concentrate (327R-16)
vial of 1.0 mL concentrate Research Use Only (327R-16-RUO)
vial of 1.0 mL pre-dilute Research Use Only (327R-17-RUO)
vial of 1.0 mL pre-dilute ready-to-use (327R-17)
vial of 7.0 mL pre-dilute ready-to-use (327R-18)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (327R-18-RUO)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:10-1:40 (concentrated)

isotype

IgG

control

prostate

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic, membranous

Gene Information

human ... FOLH1(2346)

Related Categories

General description

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein with enzymatic activity. PSMA is expressed in normal prostate epithelial cells as well as prostate neoplastic cells. It has been demonstrated that PSMA expression is increased in prostate cancer and is correlated with disease progression. Although highly sensitive and specific for prostate, PSMA also labels a subset of non-prostate tissues, including the small intestine and kidney. PSMA is useful for identifying metastatic prostate carcinoma and distinguishing prostate carcinoma from urothelial carcinoma.

Quality


IVD
IVD
IVD
RUO

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Woo Jin Oh et al.
Journal of pathology and translational medicine, 50(5), 345-354 (2016-08-09)
The pathologic distinction between high-grade prostate adenocarcinoma (PAC) involving the urinary bladder and high-grade urothelial carcinoma (UC) infiltrating the prostate can be difficult. However, making this distinction is clinically important because of the different treatment modalities for these two entities.
Arundhati Ghosh et al.
Journal of cellular biochemistry, 91(3), 528-539 (2004-02-03)
Prostate specific membrane antigen (PSMA), is a unique membrane bound glycoprotein, which is overexpressed manifold on prostate cancer as well as neovasculature of most of the solid tumors, but not in the vasculature of the normal tissues. This unique expression
Sam S Chang
Reviews in urology, 6 Suppl 10, S13-S18 (2006-09-21)
Efforts to evaluate and discover diagnostic and therapeutic markers for prostate cancer continue. One of these, prostate-specific membrane antigen (PSMA), a transmembrane protein expressed in all types of prostatic tissue, remains a useful diagnostic and possibly therapeutic target. The radio-immunoconjugate
Kurt D Bernacki et al.
Diagnostic cytopathology, 42(7), 570-575 (2013-11-26)
The diagnosis of metastatic prostate carcinoma frequently requires the use of immunohistochemical adjuncts. Immunohistochemistry for prostate-specific antigen (PSA) is commonly used for this purpose but can be of limited utility. Recently, prostate-specific membrane antigen (PSMA) has been shown to be
D A Silver et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 3(1), 81-85 (1997-01-01)
Prostate-specific membrane antigen is a type II membrane protein with folate hydrolase activity produced by prostatic epithelium. The expression of this molecule has also been documented in extraprostatic tissues, including small bowel and brain. In the present study, an extensive

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service